Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13961998 | 1.00 | MEN1 (0.60) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL505491 | 1.00 | MEN1 (0.60) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL24938850 | 0.90 | SMN1; SMN2 (0.63) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL376463 | 0.90 | SMN1; SMN2 (0.63) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1467671 | 0.90 | SMN1; SMN2 (0.63) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL14964706 | 0.88 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15946897 | 0.88 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL21356953 | 0.88 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL31106345 | 0.88 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL505013 | 0.88 | SMN1; SMN2 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20120035154-A1 | Modulators of Cellular Adhesion | SARcode Bioscience, Inc. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7989626-B2 | Modulators of cellular adhesion | SAR code Corporation (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110124625-A1 | Modulators of Cellular Adhesion | SARCODE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | MEN1 3077/4885KMT2A 1740/4885NPSR1 3898/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | MEN1 3127/4885KMT2A 2960/4885NPSR1 404/4885 |
| US-20110124625-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | MEN1 3127/4885KMT2A 2960/4885NPSR1 404/4885 |
| US-20120035154-A1 | Modulators of Cellular Adhesion | ITGB1, VCAM1, ITGB8 | MEN1 3127/4885KMT2A 2960/4885NPSR1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.